Systemtherapie des metastasierten Analkarzinoms

Fischer, Laura Elisabeth und Heinemann, Volker (2020): Systemtherapie des metastasierten Analkarzinoms. In: Onkologe, Bd. 26, Nr. 4: S. 356-361

Abstract

Background: Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy. Yet, the incidence of anal cancer continues to rise in Germany. More than 80% of all anal cancers are associated with human papillomavirus (HPV) infection. There are few prospective studies on the choice of chemotherapy in the metastatic situation. Chemotherapy is the classic systemic treatment. Immunotherapy using checkpoint inhibitors is currently being evaluated in clinical studies. Aim: An overview of the current studies for the systemic treatment of metastasized anal carcinoma is provided. Materials and methods: For this purpose, a literature search was conducted to find evidence for systemic therapeutic options for metastatic anal carcinoma. Results: Paclitaxel plus carboplatin or the combination of 5-fluorouracil (5-FU) and cisplatin can be given as first-line chemotherapy. Second-line chemotherapy has not been tested in trials to date, but may be given with a taxane or a 5-FU-based regime, depending on the initial use. Immunotherapy with nivolumab or pembrolizumab is included as a second-line treatment. Conclusion The association of HPV with anal carcinoma is gaining importance for future immunotherapeutic approaches. In addition, a multimodal therapy concept seems to have a high relevance for the prognosis of patients.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0947-8965
• Sprache: Deutsch